Article

IMPORTANCE

Considering the widespread and increasing use of biological immunomodulators (biological disease-modifying antirheumatic drugs [bDMARDs]) to treat chronic inflammatory conditions and the concern that immunomodulation may alter cancer risk and progression, the limited available data on the use of these therapies as used in clinical practice and cancer risks are a concern.

A Nationwide Cohort Study From Sweden

29.11.2017
 
Comments
Order by: 
Per page:
 
  • There are no comments yet
Actions
Rating
0 votes
Recommend